OxySure (OXYS) Launches OxyTrac(TM) to Save Lives & Help Companies Stay Compliant

Dec. 10, 2015 8:01 am

REDONDO BEACH, CA / ACCESSWIRE / December 10, 2015 / Suppose that you're at a sporting event and someone in the crowd suffers a heart attack and goes into cardiac arrest. A nearby fan responds quickly and calls for help, but stadium employees aren't quite sure where the nearest AED is located. Once a device is finally located, emergency responders attempt to utilize it, but the battery has died. The person ends up dying at the event and the sporting event is sued for their lack of an appropriate response.

OxySure Therapeutics Inc. (OTCQB: OXYS), a leading provider of emergency medical solutions, recently launched its OxyTrac(TM) technology to make sure these scenarios never occur. Through a cloud-based solution, the technology helps rapidly locate all emergency response devices on the premises, facilitates availability of extra help via a contact database, and ensures that devices are properly inspected, while tracking expiration dates for batteries or other consumables.

The OxyTrac(TM) Solution

OxyTrac(TM) is compatible with a wide array of emergency response devices, ranging from OxySure's in-house Model 615 emergency oxygen solution to AEDs produced from a variety of different manufacturers. At a price as low as $25 per device per year, the solution is a cost effective way to ensure appropriate emergency responses and legal compliance necessary to avoid lawsuits and other issues stemming from the lack of an appropriate response.

"We are excited about OxyTrac and the way it will make our customers' lives easier by consolidating the tracking, inspections, maintenance, and monitoring of all their emergency medical devices on one single platform," said Julian Ross, CEO of OxySure. "We are able to track any device with an expiry date on it, and OxyTrac can provide the confidence of knowing the filing, registration, and submission of the required compliance paperwork has been documented properly."

Investor Implications

OxyTrac(TM) addresses a large potential end market - including its existing customer base - with a high margin recurring revenue service. The company has sold thousands of its own devices over the past several years, creating a strong initial market for the service, while there are millions of commercial AED installations around the world. Capturing even a fraction of these customer segments could generate significant recurring revenue for shareholders.

In addition to generating recurring revenue from the yearly subscription fee, the technology could improve the consistency of consumable revenue from its other products. The OxySure Model 615 has reusable oxygen cartridges that must be regularly replaced to remain effective and the reminders generated from OxyTrac(TM) could ensure a steady stream of orders for new cartridges from its existing customer base over the long-term. The system automatically generates email reminders regarding upcoming expiry dates and an even create autoship options with automatic invoicing for customer convenience.

Looking Ahead

OxySure reported its 14th consecutive quarter of growth during its fiscal third quarter, with revenue growing at a nearly 40% clip to $1,138,380 for the quarter. With plans to reach a $10 million run rate by the end of the year, the company's products continue to gain traction in the market, while new product launches like OxyTrac(TM) promise to create new growth opportunities. Combined with an anticipated cash flow breakeven next year, investors may want to take a closer look.

The company also plans to pursue an uplisting to a national exchange like the NASDAQ or NYSE MKT, having appointed new board members and taken actions to meet other requirements. Upon a successful uplisting, the move could encourage institutional investors to take a closer look at the stock and potentially improve both liquidity and share price. Analysts like SeeThruEquity have assigned a $2.30 per share price target on the stock given these upcoming catalysts.

Investors in micro- or small-cap medical device companies, such as Sharps Compliance Corp. (NASDAQ: SMED), Sanuwave Health Inc. (OTC: SNWV), or Biomerica Inc. (OTC: BMRA), may want to take a closer look at the stock given these numerous catalysts.

For more information, visit the company's website at www.oxysure.com.

Legal Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx.

SOURCE: Emerging Growth LLC

Accesswire IA
December 10, 2015 - 8:01 AM EST

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President, NASDAQ Stock Market